Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies

Y. Renaudineau, E. Grunebaum, I. Krause, S. Praprotnik, R. Revelen, P. Youinou, M. Blanks, B. Gilburd, Y. Sherer, C. Luderschmidt, A. Eldor, B. Weksler, M. Eric Gershwin, Y. Shoenfeld

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: One of the main features of systemic sclerosis (SSc) is vascular damage, the mechanism of which is not understood. In the present study we examined whether screening of SSc patients for different anti-endothelial cells antibodies (AECA) of various origins increase the sensitivity of AECA detection in SSc patients. Secondary aim was an attempt to correlate AECA with other common autoantibodies. Materials & methods: 478 SSc patients were studied for the presence AECA, anti-cardiolipin (aCL), anti-dsDNA, anti-heparin (AHA), anti-pyruvate dehydrogenase (PDH) and anti-PDC-E2 autoantibodies. AECA levels were determined using human umbilical vein EC (HUVEC), bone marrow EC (BMEC), EC hybridoma (EA.hy 926) and Kaposi sarcoma EC (KS). Results: Positive AECA were found in 49.5% of SSc patients (27.1% HUVEC; 34.3% BMEC; 26.3% EaHy 926 and 22.7% KS). The highest percent reactivity of AECA was obtained using microvascular BMEC. When combining BMEC and either other cell lines the reactivity ranged from 41.4% to 46%. A significant association between AECA on the one hand and AHA (p<0.001) and anti-PDH (p<0.05) on the other was seen. Cross-reactivity with anti-PDC-E2 was excluded by inhibition tests, but AHA and anti-PDH may be part of the spectrum of AECA. Conclusions: Since false-negative AECA may result from lack of expression of various antigens on a specific EC, analysis of AECA in SSc patients requires using several EC types, including microvascular EC.

Original languageEnglish (US)
Pages (from-to)171-179
Number of pages9
JournalAutoimmunity
Volume33
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Systemic Scleroderma
Autoantibodies
Endothelial Cells
Bone Marrow
Pyruvic Acid
Heparin
Oxidoreductases
Umbilical Veins
Kaposi's Sarcoma
anti-endothelial cell antibody
Cardiolipins
Hybridomas
Blood Vessels
Antigens
Cell Line

Keywords

  • Anti-endothelial cell antibodies
  • Autoantibodies
  • Pyruvate dehydrogenase
  • Systemic sclerosis
  • Vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Renaudineau, Y., Grunebaum, E., Krause, I., Praprotnik, S., Revelen, R., Youinou, P., ... Shoenfeld, Y. (2001). Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies. Autoimmunity, 33(3), 171-179.

Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies. / Renaudineau, Y.; Grunebaum, E.; Krause, I.; Praprotnik, S.; Revelen, R.; Youinou, P.; Blanks, M.; Gilburd, B.; Sherer, Y.; Luderschmidt, C.; Eldor, A.; Weksler, B.; Gershwin, M. Eric; Shoenfeld, Y.

In: Autoimmunity, Vol. 33, No. 3, 2001, p. 171-179.

Research output: Contribution to journalArticle

Renaudineau, Y, Grunebaum, E, Krause, I, Praprotnik, S, Revelen, R, Youinou, P, Blanks, M, Gilburd, B, Sherer, Y, Luderschmidt, C, Eldor, A, Weksler, B, Gershwin, ME & Shoenfeld, Y 2001, 'Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies', Autoimmunity, vol. 33, no. 3, pp. 171-179.
Renaudineau, Y. ; Grunebaum, E. ; Krause, I. ; Praprotnik, S. ; Revelen, R. ; Youinou, P. ; Blanks, M. ; Gilburd, B. ; Sherer, Y. ; Luderschmidt, C. ; Eldor, A. ; Weksler, B. ; Gershwin, M. Eric ; Shoenfeld, Y. / Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies. In: Autoimmunity. 2001 ; Vol. 33, No. 3. pp. 171-179.
@article{8968f68ded4f41cfb5a4cf5cb984a098,
title = "Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies",
abstract = "Objective: One of the main features of systemic sclerosis (SSc) is vascular damage, the mechanism of which is not understood. In the present study we examined whether screening of SSc patients for different anti-endothelial cells antibodies (AECA) of various origins increase the sensitivity of AECA detection in SSc patients. Secondary aim was an attempt to correlate AECA with other common autoantibodies. Materials & methods: 478 SSc patients were studied for the presence AECA, anti-cardiolipin (aCL), anti-dsDNA, anti-heparin (AHA), anti-pyruvate dehydrogenase (PDH) and anti-PDC-E2 autoantibodies. AECA levels were determined using human umbilical vein EC (HUVEC), bone marrow EC (BMEC), EC hybridoma (EA.hy 926) and Kaposi sarcoma EC (KS). Results: Positive AECA were found in 49.5{\%} of SSc patients (27.1{\%} HUVEC; 34.3{\%} BMEC; 26.3{\%} EaHy 926 and 22.7{\%} KS). The highest percent reactivity of AECA was obtained using microvascular BMEC. When combining BMEC and either other cell lines the reactivity ranged from 41.4{\%} to 46{\%}. A significant association between AECA on the one hand and AHA (p<0.001) and anti-PDH (p<0.05) on the other was seen. Cross-reactivity with anti-PDC-E2 was excluded by inhibition tests, but AHA and anti-PDH may be part of the spectrum of AECA. Conclusions: Since false-negative AECA may result from lack of expression of various antigens on a specific EC, analysis of AECA in SSc patients requires using several EC types, including microvascular EC.",
keywords = "Anti-endothelial cell antibodies, Autoantibodies, Pyruvate dehydrogenase, Systemic sclerosis, Vasculitis",
author = "Y. Renaudineau and E. Grunebaum and I. Krause and S. Praprotnik and R. Revelen and P. Youinou and M. Blanks and B. Gilburd and Y. Sherer and C. Luderschmidt and A. Eldor and B. Weksler and Gershwin, {M. Eric} and Y. Shoenfeld",
year = "2001",
language = "English (US)",
volume = "33",
pages = "171--179",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Anti-endothelial cell antibodies (AECA) in systemic sclerosis - Increased sensitivity using different endothelial cell substrates and association with other autoantibodies

AU - Renaudineau, Y.

AU - Grunebaum, E.

AU - Krause, I.

AU - Praprotnik, S.

AU - Revelen, R.

AU - Youinou, P.

AU - Blanks, M.

AU - Gilburd, B.

AU - Sherer, Y.

AU - Luderschmidt, C.

AU - Eldor, A.

AU - Weksler, B.

AU - Gershwin, M. Eric

AU - Shoenfeld, Y.

PY - 2001

Y1 - 2001

N2 - Objective: One of the main features of systemic sclerosis (SSc) is vascular damage, the mechanism of which is not understood. In the present study we examined whether screening of SSc patients for different anti-endothelial cells antibodies (AECA) of various origins increase the sensitivity of AECA detection in SSc patients. Secondary aim was an attempt to correlate AECA with other common autoantibodies. Materials & methods: 478 SSc patients were studied for the presence AECA, anti-cardiolipin (aCL), anti-dsDNA, anti-heparin (AHA), anti-pyruvate dehydrogenase (PDH) and anti-PDC-E2 autoantibodies. AECA levels were determined using human umbilical vein EC (HUVEC), bone marrow EC (BMEC), EC hybridoma (EA.hy 926) and Kaposi sarcoma EC (KS). Results: Positive AECA were found in 49.5% of SSc patients (27.1% HUVEC; 34.3% BMEC; 26.3% EaHy 926 and 22.7% KS). The highest percent reactivity of AECA was obtained using microvascular BMEC. When combining BMEC and either other cell lines the reactivity ranged from 41.4% to 46%. A significant association between AECA on the one hand and AHA (p<0.001) and anti-PDH (p<0.05) on the other was seen. Cross-reactivity with anti-PDC-E2 was excluded by inhibition tests, but AHA and anti-PDH may be part of the spectrum of AECA. Conclusions: Since false-negative AECA may result from lack of expression of various antigens on a specific EC, analysis of AECA in SSc patients requires using several EC types, including microvascular EC.

AB - Objective: One of the main features of systemic sclerosis (SSc) is vascular damage, the mechanism of which is not understood. In the present study we examined whether screening of SSc patients for different anti-endothelial cells antibodies (AECA) of various origins increase the sensitivity of AECA detection in SSc patients. Secondary aim was an attempt to correlate AECA with other common autoantibodies. Materials & methods: 478 SSc patients were studied for the presence AECA, anti-cardiolipin (aCL), anti-dsDNA, anti-heparin (AHA), anti-pyruvate dehydrogenase (PDH) and anti-PDC-E2 autoantibodies. AECA levels were determined using human umbilical vein EC (HUVEC), bone marrow EC (BMEC), EC hybridoma (EA.hy 926) and Kaposi sarcoma EC (KS). Results: Positive AECA were found in 49.5% of SSc patients (27.1% HUVEC; 34.3% BMEC; 26.3% EaHy 926 and 22.7% KS). The highest percent reactivity of AECA was obtained using microvascular BMEC. When combining BMEC and either other cell lines the reactivity ranged from 41.4% to 46%. A significant association between AECA on the one hand and AHA (p<0.001) and anti-PDH (p<0.05) on the other was seen. Cross-reactivity with anti-PDC-E2 was excluded by inhibition tests, but AHA and anti-PDH may be part of the spectrum of AECA. Conclusions: Since false-negative AECA may result from lack of expression of various antigens on a specific EC, analysis of AECA in SSc patients requires using several EC types, including microvascular EC.

KW - Anti-endothelial cell antibodies

KW - Autoantibodies

KW - Pyruvate dehydrogenase

KW - Systemic sclerosis

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=0034915979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034915979&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 171

EP - 179

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 3

ER -